Rheumatoid arthritis (RA)
Anne Davidson, MBBS;FRACP
Feinstein Institutes for Medical Research
Manhasset, New York, United States
Disclosure information not submitted.
Rheumatoid arthritis (RA) affects 0.6 percent of the U.S. adult population. Although many new drugs are available, only 60-70% of patients respond to each drug and many patients only respond for a limited period of time. Little is still known about the heterogeneity of inflammatory responses in the joints and how to best direct treatment for each patient. The Accelerating Medicines Partnership has addressed this question using a multi-omics approach applied to peripheral blood and synovial tissues. This session will address the role of B cells in the pathogenesis of RA including their phenotype, heterogeneity, and their role in promoting bone erosion.
Speaker: Jennifer Anolik, MD;PhD – University of Rochester Medical Center